BioSig Technologies (NASDAQ:BSGM) released its quarterly earnings results on Monday. The company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03), Fidelity Earnings reports.
BioSig Technologies stock opened at $6.46 on Wednesday. BioSig Technologies has a 1-year low of $3.50 and a 1-year high of $7.88.
In other news, CEO Kenneth L. Londoner acquired 18,700 shares of the firm’s stock in a transaction dated Tuesday, January 22nd. The stock was bought at an average price of $4.35 per share, with a total value of $81,345.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 26.70% of the stock is currently owned by company insiders.
Several research firms have recently commented on BSGM. Zacks Investment Research cut shares of BioSig Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday. Laidlaw set a $11.00 price objective on shares of BioSig Technologies and gave the company a “buy” rating in a research note on Wednesday, February 20th.
About BioSig Technologies
BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.
Featured Article: Do closed-end mutual funds pay dividends?
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.